DanCann Pharma A/S with inspection by the Danish Medicine Agency during Q4-2022: expects to get EU-GMP approval before end-2022 - Marketscreener.com

COPENHAGEN, Denmark, November 8, 2022 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" oregon the "Company"), a Danish institution powered by cannabinoids, hereby announces that the Company expects to get the EU-GMP support of the accumulation facilities Biotech Pharm1 ("BP1") successful Q4 2022.

Earlier this twelvemonth DanCann Pharma applied for support of the accumulation facilities BP1. The Danish Medical Agency has informed the Company, that the inspection volition instrumentality spot successful Q4 of 2022. The support volition beryllium the astir important milestone truthful acold for DanCann Pharma and volition unfastened further marketplace possibilities for the Company.  

During 2022 DanCann Pharma has tally a important fig of tests successful BP1 successful Ansager. At the aforesaid time, the Company has optimized each process and strategy successful bid to comply with requirements for the accumulation of aesculapian cannabis successful Denmark and Europe.  

Now the Company is acceptable to beryllium inspected from the Danish Medicines Agency successful bid to beryllium approved according to EU-GMP standards. The support is expected to beryllium successful spot successful 2022. 

Jeppe Krog Rasmussen CEO of DanCann Pharma, comments: 

- The EU-GMP certification of the installation is simply a designation of our work, and an important measurement connected the mode to achieving prime assured products for partners, and yet for the patients. This is indispensable for the Company's legitimacy to the market. Uniform merchandise contented and a absorption connected delivering the aforesaid prime from clip to clip is simply a warrant that DanCann Pharma is obliged to springiness to patients who tin payment from a attraction with aesculapian cannabis and cannabinoids. DanCann Pharma was established to marque a quality for patients, and we volition ne'er compromise connected that. 

BP1 is built connected champion practices from the pharmaceutical manufacture successful operation with precocious environmentally controlled manufacturing exertion and vertical cultivation. Selected genetics are developed successful multi-storey systems without the usage of ungraded oregon different media, but with a specially developed strategy that adds the required magnitude of fluid and nutrients.

Jeppe Krog Rasmussen comments: 

- The support marks a important and defining way connected the travel for DanCann Pharma - thing we person been moving towards for a agelong time. DanCann Pharma is connected the borderline of transforming from a task to an existent operation. We are acceptable to marque a recognizable interaction connected the aesculapian cannabis markets successful Denmark and successful Europe.  

Following the support of the facilities, DanCann Pharma faces its biggest milestone to day erstwhile the archetypal batch of biomaterial is acceptable for transportation successful the archetypal fractional of 2023 from BP1. 

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) was founded successful 2018 and is simply a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is simply a vertically integrated, licensed accumulation and organisation Company based successful Denmark. The Company focuses connected discovering, developing, manufacturing, and commercializing caller therapeutic cannabinoids successful a wide scope of illness areas.

DanCann Pharma A/S (SS: DANCAN) is listed connected the Spotlight Stock Market successful Copenhagen.

For much information, visit: www.dancann.com  

For further information, delight contact:

Jeppe Krog Rasmussen, CEO

E-mail: jkr@dancann.com  

Website: www.dancann.com  

Disclaimer

Some statements successful this merchandise whitethorn incorporate forward-looking information. All statements, different than of humanities fact, that code activities, events, oregon developments that the Company believes, expects, oregon anticipates volition oregon whitethorn hap successful the aboriginal (including, without limitation, statements regarding imaginable acquisitions and financings) are forward-looking statements. Forward-looking statements are mostly identifiable by usage of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" oregon "project" oregon the antagonistic of these words oregon different variations connected these words oregon comparable terminology.

Forward-looking statements are taxable to respective risks and uncertainties, galore of which are beyond the Company's quality to power oregon predict, that whitethorn origin the existent results of the Company to disagree materially from those discussed successful the forward-looking statements. Factors that could origin existent results oregon events to disagree materially from existent expectations include, among different things, without limitation, the inability of the Company, to get capable financing to execute the Company's concern plan; competition; regularisation and anticipated and unanticipated costs and delays, the occurrence of the Company's probe strategies, the applicability of the discoveries made therein, the palmy and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory oregon intelligence spot decisions and different risks disclosed successful the Company's nationalist disclosure grounds connected record with the applicable securities regulatory authorities.

Although the Company has attempted to place important factors that could origin existent results oregon events to disagree materially from those described successful forward-looking statements, determination whitethorn beryllium different factors that origin results oregon events not to beryllium arsenic anticipated, estimated oregon intended. Readers should not spot undue reliance connected forward-looking statements. The forward-looking statements included successful this presumption are made arsenic of the day of this presumption and the Company does not undertake an work to publically update specified forward-looking statements to bespeak caller information, consequent events oregon different unless required by applicable securities legislation.

https://news.cision.com/dancann-pharma/r/dancann-pharma-a-s-with-inspection-by-the-danish-medicine-agency-during-q4-2022--expects-to-get-eu-g,c3663148

https://mb.cision.com/Main/19875/3663148/1654724.pdf

(c) 2022 Cision. All rights reserved., root Press Releases - English